氯氮平抵抗性精神病患者的洛沙平治疗。

The Mental Health Clinician Pub Date : 2021-07-16 eCollection Date: 2021-07-01 DOI:10.9740/mhc.2021.07.263
Jennifer Erley, Sarah Goldsborough, Amy VandenBerg, Alexandra Audu
{"title":"氯氮平抵抗性精神病患者的洛沙平治疗。","authors":"Jennifer Erley,&nbsp;Sarah Goldsborough,&nbsp;Amy VandenBerg,&nbsp;Alexandra Audu","doi":"10.9740/mhc.2021.07.263","DOIUrl":null,"url":null,"abstract":"<p><p>Clozapine is recognized as the drug of choice for treatment-refractory schizophrenia, but use may be limited because of strict monitoring requirements and adverse effects including severe neutropenia, seizures, and myocarditis. Loxapine is a first-generation antipsychotic with similarities to clozapine in both structure and receptor binding. This case describes a 57-year-old male with a history of severe paranoid schizophrenia despite treatment with clozapine and other psychotropic agents, who experienced clinical improvement after a cross titration from clozapine to loxapine. Loxapine may be a reasonable alternative in patients with treatment-refractory schizophrenia who do not tolerate or respond to clozapine.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"11 4","pages":"263-266"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/10/i2168-9709-11-4-263.PMC8287867.pdf","citationCount":"3","resultStr":"{\"title\":\"Loxapine in patient with clozapine-resistant psychosis.\",\"authors\":\"Jennifer Erley,&nbsp;Sarah Goldsborough,&nbsp;Amy VandenBerg,&nbsp;Alexandra Audu\",\"doi\":\"10.9740/mhc.2021.07.263\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Clozapine is recognized as the drug of choice for treatment-refractory schizophrenia, but use may be limited because of strict monitoring requirements and adverse effects including severe neutropenia, seizures, and myocarditis. Loxapine is a first-generation antipsychotic with similarities to clozapine in both structure and receptor binding. This case describes a 57-year-old male with a history of severe paranoid schizophrenia despite treatment with clozapine and other psychotropic agents, who experienced clinical improvement after a cross titration from clozapine to loxapine. Loxapine may be a reasonable alternative in patients with treatment-refractory schizophrenia who do not tolerate or respond to clozapine.</p>\",\"PeriodicalId\":22710,\"journal\":{\"name\":\"The Mental Health Clinician\",\"volume\":\"11 4\",\"pages\":\"263-266\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/10/i2168-9709-11-4-263.PMC8287867.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Mental Health Clinician\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.9740/mhc.2021.07.263\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Mental Health Clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/mhc.2021.07.263","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

摘要

氯氮平被认为是治疗难治性精神分裂症的首选药物,但由于严格的监测要求和包括严重中性粒细胞减少症、癫痫发作和心肌炎在内的不良反应,氯氮平的使用可能受到限制。洛沙平是第一代抗精神病药物,在结构和受体结合方面与氯氮平相似。本病例描述了一名57岁男性患者,尽管曾接受氯氮平和其他精神药物治疗,但仍有严重的偏执型精神分裂症病史,经氯氮平与洛沙平交叉滴定后,临床得到改善。对于对氯氮平无耐受或反应的难治性精神分裂症患者,氯氮平可能是一种合理的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Loxapine in patient with clozapine-resistant psychosis.

Clozapine is recognized as the drug of choice for treatment-refractory schizophrenia, but use may be limited because of strict monitoring requirements and adverse effects including severe neutropenia, seizures, and myocarditis. Loxapine is a first-generation antipsychotic with similarities to clozapine in both structure and receptor binding. This case describes a 57-year-old male with a history of severe paranoid schizophrenia despite treatment with clozapine and other psychotropic agents, who experienced clinical improvement after a cross titration from clozapine to loxapine. Loxapine may be a reasonable alternative in patients with treatment-refractory schizophrenia who do not tolerate or respond to clozapine.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review Impact of Board Certified Psychiatric Pharmacists on improving urinary tract infection antibiotic appropriateness at an acute psychiatric hospital Barriers to access to psychiatric medications in Missouri county jails Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports Intranasal ketamine as a treatment for psychiatric complications of long COVID: A case report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1